Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
*After 68 weeks, participants administering once-weekly semaglutide treatment (combined with diet and exercise) experienced an average of 14.9% reduction in body weight, compared with 2.4% for the placebo
This article examines the evidence for blood pressure reduction with GLP-1 therapy, identifies which patients may benefit most from this additional effect, and outlines important safety considerations
The near-term battle is now moving into pills
Below is an overview of how the two compare: Mechanism of Action: Retatrutide: Triple agonist (GLP-1, GIP, glucagon) Zepbound: Dual agonist (GLP-1, GIP) Developer: Retatrutide: Eli Lilly and Company (investigational) Zepbound: Eli Lilly and Company (approved) Regulatory Status: Retatrutide: Phase III clinical development Zepbound: FDA-approved for obesity, obstructive sleep apnea Weight Loss Efficacy: Retatrutide: Up to ~28.7% (68 weeks
:max_bytes(150000):strip_icc()/bleeding-between-periods-3520522-v11-f83f2f2eefea4365aae299fcd4eebcfd.png)
